Tenderwize
Zurück zur Suche

Open-House Biologics Discount Agreements 2026-05 - Pegfilgrastim

Techniker Krankenkasse·Hamburg, Germany·Deadline Apr 29, 2028 · 614 days left·Open·Supplies
Registrieren zum SpeichernOpen documents
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-05 - Pegfilgrastim

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

50 / 100

Komplexität

20 / 100

Risikofaktoren

No estimated contract value or framework maximum value is disclosed. Potential revenue is unknown.

The procedure is not a public procurement under EU directives; legal recourse is via social courts, not procurement tri...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Apr 2028
  • Supply of Pegfilgrastim pharmaceutical products under discount agreements.
  • Nationwide coverage in Germany.
Vollständige Zusammenfassung anzeigen

Open-House procedure for pharmaceutical discount agreements (Rabattverträge) for the active substance Pegfilgrastim, conducted by Techniker Krankenkasse (lead buyer) together with HEK and hkk. The procedure is open to all eligible pharmaceutical entrepreneurs at any time during the contract period. No estimated value, no award criteria, and no procurement documents were analyzed. The contract duration is 24 months from May 2026 to April 2028.

Risiken

No estimated contract value or framework maximum value is disclosed. Potential revenue is unknown.

The procedure is not a public procurement under EU directives; legal recourse is via social courts, not procurement tri...

Wichtige Anforderungen

Technical

  • Must be a pharmaceutical entrepreneur according to § 4 Abs. 18 AMG for the offered medicines.
  • Must have a valid marketing authorization for the medicine(s) in Germany or equivalent.

Administrative

  • Must submit a self-declaration on authorization and company (Anlage 4 zum Vertrag).

Anforderungen können unvollständig sein.

Auftraggeber

Ort

Hamburg, DEU

Kennung

992-80116-93

Tätigkeit

Health

Lose (1)

LOT-0001

Open-House Biologics Discount Agreements 2026-05 - Pegfilgrastim

Conclusion of pharmaceutical discount agreements according to § 130a Abs. 8 SGB V for Pegfilgrastim via an open-house procedure. All eligible pharmaceutical entrepreneurs can join at any time during the contract period. No exclusivity is granted.

SuppliesEU fundedElectronic submission

Ort

DE600, Germany

Dauer

Apr 2026 - Apr 2028

Kategorie

Pharmaceutical products

Frist

Deadline Apr 29, 2028

Vergabedetails

Veröffentlichungsdatum
18 Mar 2026
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
190019-2026

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3